Anti CD20 MOAB (Mabthera) in treatment of Waldenstrom macroglobulinemia (Case report)

Ве молиме користете го овој идентификатор да го цитирате или поврзете овој запис: http://hdl.handle.net/20.500.12188/11622

DC Field	Value	Language
dc.contributor.author	L. Cevreska	en_US
dc.contributor.author	D. Efremov	en_US
dc.contributor.author	S. Genadieva Stavric	en_US
dc.contributor.author	M. Pavkovic	en_US
dc.contributor.author	S. Stankovic	en_US
dc.contributor.author	M. Ivanovski	en_US
dc.contributor.author	N. Siljanovski	en_US
dc.date.accessioned	2021-04-02T10:03:12Z	-
dc.date.available	2021-04-02T10:03:12Z	-
dc.date.issued	2003	-
dc.identifier.uri	http://hdl.handle.net/20.500.12188/11622	-
dc.language.iso	en	en_US
dc.publisher	European Hematology Association	en_US
dc.relation.ispartof	The Hematology Journal	en_US
dc.subject	Waldenstrom macroglobulinemia	en_US
dc.subject	Mabthera (Rituximab)	en_US
dc.subject	Case report	en_US
dc.title	Anti CD20 MOAB (Mabthera) in treatment of Waldenstrom macroglobulinemia (Case report)	en_US
dc.type	Proceeding article	en_US
dc.relation.conference	The 8-the Annual Congress of the European Hematology Association, Lyon, France, 12-15 June 2003	en_US
item.grantfulltext	open	-
item.fulltext	With Fulltext	-
crisitem.author.dept	Faculty of Medicine	-
crisitem.author.dept	Faculty of Medicine	-
crisitem.author.dept	Faculty of Medicine	-
Appears in Collections:	Faculty of Medicine: Conference papers